| My Account | Subscribe | Contact Us | Donate |
Home
- Kris Freeman Skis for Olympic Gold
- Good Insulin Injection Practices
- Etiquette for People without Diabetes
- Diabetes Technology and Intimacy
- An American in the UK: Healthcare for Type 1s
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Actos Articles
Actos and Avandia: New Heart Risk Studies
Oct 5, 2007
The September 2007 Journal of the American Medical Association (JAMA) has published two new studies, one a meta-analysis of Avandia (rosiglitazone) and the other a meta-analysis of Actos (pioglitazone).
Although both drugs are thiazolidinediones, which help control glucose by increasing sensitivity to insulin, they work in different ways. And the news is not good for beleaguered Avandia (and not all that rosy for Actos, either).
The Avandia study, which looked at four long-term trials comprising 14,291 people, found that Avandia increased risk of heart attack by 42 percent and doubled risk of heart failure, but did not increase the risk of cardiovascular death. The findings about heart attack risk were essentially the same as those of an earlier JAMA meta-analysis of shorter-term studies, the one that ignited the recent controversy over Avandia's safety.
The Actos meta-analysis looked at nineteen trials comprising more than 16,000 patients. It found that Actos lowered risk of heart attack, stroke, and death by 18 percent, but raised risk of heart failure by forty percent.
In essence, both drugs increase risk of heart failure, a problem that is highlighted by the FDA black box warnings now required on both drugs. The difference lies in their effect on risk of heart attack, which Avandia raises and Actos apparently lowers, possibly because of their differing effects on cholesterol.
The Actos meta-analysis was funded by Actos' manufacturer, Takeda. Avandia's manufacturer, GlaxoSmithKline, pooh-poohed the positive finding about Actos, indicating that it was too heavily based on one flawed Takeda-funded study and that there is no difference in safety between the two drugs.
Sources: CBS News; EurekAlert; Medline Plus
Categories: Actos, Heart Care & Heart Disease, Pharmacy, Type 2 Issues, Type 2 Medications
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
0 comments -
Oct 5, 2007 -
Email to a Friend
Send a link to this page to your friends and colleagues.